帕唑帕尼治疗晚期恶性及去分化孤立性纤维瘤:一项多中心、单臂、2期试验
这项多中心单臂2期试验在西班牙、意大利和法国16家三级医院纳入36例恶性或去分化孤立性纤维瘤患者,口服帕唑帕尼800 mg每日一次。35例可评估患者中18例(51%,95%CI 34-69)达部分缓解,常见≥3级不良事件为高血压(31%)、中性粒细胞减少(11%)等,无治疗相关死亡。作者认为帕唑帕尼安全性可控且显示活性,或可作为晚期恶性孤立性纤维瘤全身治疗的选择。
要点
- 帕唑帕尼800 mg每日一次口服治疗晚期恶性或去分化孤立性纤维瘤。
- 35例可评估患者中18例(51%,95%CI 34-69)按Choi标准达部分缓解。
- 最常见≥3级不良事件为高血压(36例中11例,31%),无治疗相关死亡。
核心结论
- 据作者所知,这是首个评估帕唑帕尼治疗恶性孤立性纤维瘤的试验,显示该药在此患者群体中有活性。
- 作者认为,帕唑帕尼毒性可控且显示活性,该药或可作为晚期恶性孤立性纤维瘤全身治疗的选择,并为未来试验提供基准。
研究设计与样本
- 单臂2期试验,在西班牙、意大利和法国的16家具备肉瘤诊疗专长的三级医院入组患者。
- 纳入年龄≥18岁、组织学确诊的转移性或不可切除恶性或去分化孤立性纤维瘤(任何部位)、既往6个月内按RECIST和Choi标准进展、ECOG体能状态0-2分的成人患者。
- 治疗方案为帕唑帕尼800 mg每日一次口服,空腹服用(餐前至少1小时或餐后至少2小时),直至疾病进展或不耐受。
- 主要终点为在意向治疗人群中可评估子集(接受至少1个月治疗且至少完成一次影像学评估的患者)按Choi标准评估的总体缓解率;安全性分析纳入所有接受至少一剂研究药物的患者。
- 2014年6月26日至2016年11月24日期间评估40例患者,最终入组36例(34例恶性孤立性纤维瘤,2例去分化孤立性纤维瘤);中位随访27个月(IQR 16-31)。
主要发现
- 基于中心影像学审查,35例可评估患者中18例(51%)按Choi标准达部分缓解,9例(26%)疾病稳定,8例(23%)疾病进展。
- 35例患者中51%(95%CI 34-69)按Choi标准达到总体缓解。
- 35例患者中10例(29%)死亡。
- 无不良事件相关死亡;最常见的≥3级不良事件为高血压(36例中11例,31%)、中性粒细胞减少(4例,11%)、丙氨酸氨基转移酶升高(4例,11%)和胆红素升高(3例,8%)。
- 在计划中期分析发现去分化孤立性纤维瘤患者出现早期快速进展后,停止了该亚组的继续入组。
关键数值与推荐
- 主要终点总体缓解率按Choi标准评估:35例可评估患者中51%(95%CI 34-69)达到总体缓解。
- 按Choi标准的最佳总体疗效:部分缓解18/35例(51%),疾病稳定9/35例(26%),疾病进展8/35例(23%)。
- 安全性:36例接受至少一剂帕唑帕尼的患者中,≥3级高血压11例(31%)、中性粒细胞减少4例(11%)、丙氨酸氨基转移酶升高4例(11%)、胆红素升高3例(8%);无治疗相关死亡。
临床怎么用
- 作者认为帕唑帕尼毒性可控且显示活性,或可作为晚期恶性孤立性纤维瘤全身治疗的选择,并为未来试验提供基准。
局限性
- 去分化孤立性纤维瘤亚组在计划中期分析发现早期快速进展后停止继续入组,该亚组仅纳入2例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A solitary fibrous tumour is a rare soft-tissue tumour with three clinicopathological variants: typical, malignant, and dedifferentiated. Preclinical experiments and retrospective studies have shown different sensitivities of solitary fibrous tumour to chemotherapy and antiangiogenics. We therefore designed a trial to assess the activity of pazopanib in a cohort of patients with malignant or dedifferentiated solitary fibrous tumour. The clinical and translational results are presented here. METHODS: In this single-arm, phase 2 trial, adult patients (aged ≥ 18 years) with histologically confirmed metastatic or unresectable malignant or dedifferentiated solitary fibrous tumour at any location, who had progressed (by RECIST and Choi criteria) in the previous 6 months and had an ECOG performance status of 0-2, were enrolled at 16 third-level hospitals with expertise in sarcoma care in Spain, Italy, and France. Patients received pazopanib 800 mg once daily, taken orally without food, at least 1 h before or 2 h after a meal, until progression or intolerance. The primary endpoint of the study was overall response measured by Choi criteria in the subset of the intention-to-treat population (patients who received at least 1 month of treatment with at least one radiological assessment). All patients who received at least one dose of the study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02066285, and with the European Clinical Trials Database, EudraCT number 2013-005456-15. FINDINGS: From June 26, 2014, to Nov 24, 2016, of 40 patients assessed, 36 were enrolled (34 with malignant solitary fibrous tumour and two with dedifferentiated solitary fibrous tumour). Median follow-up was 27 months (IQR 16-31). Based on central radiology review, 18 (51%) of 35 evaluable patients had partial responses, nine (26%) had stable disease, and eight (23%) had progressive disease according to Choi criteria. Further enrolment of patients with dedifferentiated solitary fibrous tumour was stopped after detection of early and fast progressions in a planned interim analysis. 51% (95% CI 34-69) of 35 patients achieved an overall response according to Choi criteria. Ten (29%) of 35 patients died. There were no deaths related to adverse events and the most frequent grade 3 or higher adverse events were hypertension (11 [31%] of 36 patients), neutropenia (four [11%]), increased concentrations of alanine aminotransferase (four [11%]), and increased concentrations of bilirubin (three [8%]). INTERPRETATION: To our knowledge, this is the first trial of pazopanib for treatment of malignant solitary fibrous tumour showing activity in this patient group. The manageable toxicity profile and the activity shown by pazopanib suggests that this drug could be an option for systemic treatment of advanced malignant solitary fibrous tumour, and provides a benchmark for future trials. FUNDING: Spanish Group for Research on Sarcomas (GEIS), Italian Sarcoma Group (ISG), French Sarcoma Group (FSG), GlaxoSmithKline, and Novartis.
引用
- Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018. PMID: 30578023. doi:10.1016/S1470-2045(18)30676-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。